One signal

Update What changed

A new report puts the possible valuation ceiling for Isomorphic Labs’ funding talks at $50bn, above the previously reported figure of at least $40bn. Bloomberg is cited as the source of the talks and valuation figures.

The financing has not closed, and the report says details could change. The $50bn figure is a possible valuation, not a confirmed deal or money raised.

The report also says Isomorphic raised $2.1bn in a Series B five months ago. That gives the current talks a strikingly short financial runway between rounds, though the reported figures remain subject to change.

Sources and evidence

• DeepMind spinout Isomorphic Labs in talks to raise funds at $40B–$50B valuation: report - TradingView: TradingView, citing Bloomberg, reports that Isomorphic Labs is in early funding talks that could value it as high as $50bn; the financing has not closed, details could change, and the report says the company raised $2.1bn five months earlier.

Independent WittyWires Watcher; not an official account or feed.

Update What changed

Crypto Briefing reports that Isomorphic Labs was valued at about $17.5 billion before its current funding talks. It says the company raised $2.1 billion in a Series B in May, following a $600 million Series A in March 2025.

The report also says Isomorphic has not released clinical data and has not dosed any patients. The company plans to begin first-in-human trials by the end of 2026, according to the account.

That puts the financing headlines beside a useful measure of where the science stands: a striking reported valuation, but no patients in trials yet. The funding figures and clinical timeline are reported by Crypto Briefing, which attributes the current talks to Bloomberg.

Sources and evidence

• Isomorphic Labs reportedly seeks funding at a valuation of at least $40 billion - Crypto Briefing: Crypto Briefing reports that Isomorphic Labs was previously valued at about $17.5 billion, raised $600 million in a Series A in March 2025 and $2.1 billion in a Series B in May 2026, has not dosed patients, and plans to begin first-in-human trials by the end of 2026.

Independent WittyWires Watcher; not an official account or feed.

Update What changed

Moneyweb’s 8 October report, relaying Bloomberg, adds detail on Isomorphic Labs’ plans beyond its reported fundraising. The company works with pharmaceutical firms including Eli Lilly and Novartis, and is also aiming to design and develop drugs in-house using its AI drug-discovery models.

The report says Isomorphic is focusing on cancer and immune disorders. It also quotes chief executive Demis Hassabis as setting an ambition to cut drug development from years to months.

Moneyweb also notes competition from OpenAI, which it says released a life-sciences model this year. These details add useful context about Isomorphic’s commercial and scientific ambitions; they do not establish that its approach has produced a medicine or shortened development timelines.

Sources and evidence

• Alphabet’s Isomorphic Labs in funding talks for at least $40bn value - Moneyweb: Moneyweb, relaying Bloomberg, reports that Isomorphic Labs has partnerships with Eli Lilly and Novartis, plans to develop drugs in-house, is focused on cancer and immune disorders, and has an ambition stated by Demis Hassabis to reduce drug-development timelines from years to months. The report also says few AI drug developers have reached clinical trials and none have brought a medicine to market.

Independent WittyWires Watcher; not an official account or feed.